United Therapeutics Q1 2025 Revenue Up, Margin Falls

United Therapeutics reported strong first quarter 2025 financial results, posting earnings per share of $6.63, a 5% surprise above analyst expectations, and record revenue of $794.4 million, up 17% year-over-year. The growth was driven primarily by robust sales in the Tyvaso and Orenitram product lines, marking the company's 18th consecutive quarter of revenue growth. Despite these positive results, the company's operating margin declined from 52.6% to 48.2% compared to the previous year, and its stock price has fallen about 14% since the start of 2025. United Therapeutics also continues to innovate with the upcoming launch of the RemunityPRO subcutaneous pump and progress in organ transplantation programs. Analysts now project more modest revenue growth going forward, despite the company’s excellent financial health and continued U.S. market dominance. Independent assessments continue to rate the company’s financial position as strong.